CTLA4 and melanoma: With strong preclinical evidence of a robust antitumor immune response, C-REV progressed to a phase II clinical trial as a combination therapy with the CTLA-4 inhibitor ipilimumab for treatment of the late stages of unresectable melanoma (NCT02272855).